Publication at Third Faculty of Medicine |
2018
Abstract
The aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach.
The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin.